Insmed is a biopharmaceutical company dedicated to improving the lives of patients battling serious lung diseases. In 2000, Insmed went public (NASDAQ: INSM).
Subscribe to get our research
the moment it’s released.
As compute costs fall and models mature, sustaining a competitive edge in global drug development requires innovation across the entire data infrastructure stack. Biology-native data, agentic workflows, and lab automation will define the next generation of leading biotechs.
As the global life sciences industry aims to manage costs and accelerate launches, AI is rewriting how services and software are delivered.
The shift towards single-speciality hospitals and clinics is becoming the preferred model in Indian healthcare, as insurance coverage has doubled in the past decade.
